OneSkin, a San Francisco-based skin longevity brand grounded in biotech and scientific research, has received a $20 million Series A investment from growth equity firm Prelude Growth Partners, according to the company. The funding marks a strategic inflection point for OneSkin as it advances its mission to extend skin health and functionality through cellular-level interventions.
The company said this investment will support expansion across research and development, product innovation, and broader operational capabilities. Prelude Growth’s involvement follows proactive outreach to OneSkin and replaces an early seed-stage investor, positioning the brand for its next phase of growth.
OneSkin claims its proprietary peptide, OS-01, targets senescent cells—aging cells that contribute to inflammation, collagen breakdown, and visible signs of aging—to support skin health at the root level. The company’s expanding product pipeline includes topical and supplement formats such as FACE, BODY, EYE, LIP, and HAIR offerings.
This capital infusion signals confidence in OneSkin’s science-driven approach and provides resources to scale its operations and reach within the growing skin longevity market.
